Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SUPAC-like container closure guidance for post-approval changes suggested by PhRMA.

This article was originally published in The Tan Sheet

Executive Summary

SUPAC-LIKE GUIDANCE FOR CONTAINER CLOSURE POST-APPROVAL CHANGES should be considered, the Pharmaceutical Research & Manufacturers Association says in Nov. 14 comments on FDA's draft guidance on "Submission of Documentation in Drug Applications for Container Closure Systems Used for the Packaging of Human Drugs and Biologics." Consideration should be given to "developing a separate guidance for post-approval packaging changes," PhRMA suggests. The guidance "should follow the paradigm established" in recently issued Scale-Up and Post-Approval Changes guidances, PhRMA adds, to "provide more flexibility for manufacturers without compromising quality."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel